BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Delgado-Fernández M, García-Gemar GM, Fuentes-López A, Muñoz-Pérez MI, Oyonarte-Gómez S, Ruíz-García I, Martín-Carmona J, Sanz-Cánovas J, Castaño-Carracedo MÁ, Reguera-Iglesias JM, Ruíz-Mesa JD. Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency - Three consecutive cases and review of the literature. Enferm Infecc Microbiol Clin (Engl Ed) 2021:S0213-005X(21)00035-5. [PMID: 33741148 DOI: 10.1016/j.eimc.2021.01.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Mehew J, Johnson R, Roberts D, Griffiths A, Harvala H. Convalescent plasma for COVID ‐19: Donor demographic factors associated high neutralising antibody titres. Transfusion Medicine. [DOI: 10.1111/tme.12868] [Reference Citation Analysis]
2 Senefeld JW, Klassen SA, Ford SK, Senese KA, Wiggins CC, Bostrom BC, Thompson MA, Baker SE, Nicholson WT, Johnson PW, Carter RE, Henderson JP, Hartman WR, Pirofski LA, Wright RS, Fairweather L, Bruno KA, Paneth NS, Casadevall A, Joyner MJ. Use of convalescent plasma in COVID-19 patients with immunosuppression. Transfusion 2021;61:2503-11. [PMID: 34036587 DOI: 10.1111/trf.16525] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
3 Ljungquist O, Lundgren M, Iliachenko E, Månsson F, Böttiger B, Landin-Olsson M, Wikén C, Rosendal E, Överby AK, Wigren BJ, Forsell MNE, Kjeldsen-Kragh J, Rasmussen M, Kahn F, Holm K. Convalescent plasma treatment in severely immunosuppressed patients hospitalized with COVID-19: an observational study of 28 cases. Infect Dis (Lond) 2021;:1-9. [PMID: 34878955 DOI: 10.1080/23744235.2021.2013528] [Reference Citation Analysis]
4 Boggiano C, Eisinger RW, Lerner AM, Anderson JM, Woodcock J, Fauci AS, Collins FS. Update on and Future Directions for Use of Anti-SARS-CoV-2 Antibodies: National Institutes of Health Summit on Treatment and Prevention of COVID-19. Ann Intern Med 2021. [PMID: 34724404 DOI: 10.7326/M21-3669] [Reference Citation Analysis]
5 Casarola G, D'Abbondanza M, Curcio R, Alcidi R, Campanella T, Rossi R, Fusaro J, Gandolfo V, Di Giuli C, Laoreti C, Veca V, Leone MC, Pucci G, Vaudo G. Efficacy of convalescent plasma therapy in immunocompromised patients with COVID-19: A case report. Clin Infect Pract 2021;12:100096. [PMID: 34490417 DOI: 10.1016/j.clinpr.2021.100096] [Reference Citation Analysis]
6 Focosi D, Franchini M, Pirofski LA, Maggi F, Casadevall A. Is SARS-CoV-2 viral clearance in nasopharyngeal swabs an appropriate surrogate marker for clinical efficacy of neutralising antibody-based therapeutics? Rev Med Virol 2021;:e2314. [PMID: 34861088 DOI: 10.1002/rmv.2314] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Focosi D, Franchini M. Potential use of convalescent plasma for SARS-CoV-2 prophylaxis and treatment in immunocompromised and vulnerable populations. Expert Rev Vaccines 2021;:1-8. [PMID: 34015243 DOI: 10.1080/14760584.2021.1932475] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Beraud M, Goodhue Meyer E, Lozano M, Bah A, Vassallo R, Brown BL. Lessons learned from the use of convalescent plasma for the treatment of COVID-19 and specific considerations for immunocompromised patients. Transfusion and Apheresis Science 2022. [DOI: 10.1016/j.transci.2022.103355] [Reference Citation Analysis]
9 Bucciol G, Tangye SG, Meyts I. Coronavirus disease 2019 in patients with inborn errors of immunity: lessons learned. Curr Opin Pediatr 2021;33:648-56. [PMID: 34734915 DOI: 10.1097/MOP.0000000000001062] [Reference Citation Analysis]